{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:58:06Z","timestamp":1783421886075,"version":"3.54.6"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["81871276"],"award-info":[{"award-number":["81871276"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This retrospective cohort study aimed to find out predictors and early biomarkers of Infliximab (IFX) refractory intestinal Beh\u00e7et\u2019s syndrome (intestinal BS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We collected the baseline clinical characteristics, laboratory parameters, and concomitant therapies of intestinal BS patients treated by IFX from the Shanghai Beh\u00e7et\u2019s syndrome database. After 1\u2009year IFX therapy, intestinal BS patients with non-mucosal healing (NMH, intestinal ulcers detected by colonoscopy) and\/or no clinical remission [NCR, scores of the disease activity index for intestinal Beh\u00e7et\u2019s disease (DAIBD)\u2009\u226520] were defined as IFX refractory intestinal BS. Multivariate logistic regression analysis was performed to evaluate the predictors for NMH and NCR in IFX refractory intestinal BS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In 85 intestinal BS patients, NMH was identified in 29 (34.12%) patients, and NCR was confirmed in 20 (23.53%) patients. Erythrocyte sedimentation rate (ESR; \u226524\u2009mm\/h) and free triiodothyronine (fT3; \u22643.3pmol\/L) were the independent risk factors of NMH in IFX refractory intestinal BS. Drinking alcohol and the fT3\/free thyroxine ratio (fT3\/fT4; \u22640.24) were independent risk factors, and thalidomide was an independent protective factor, for NCR in intestinal BS patients treated by IFX.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study may be applicable for adjusting the therapeutic strategy and sidestepping unnecessary exposure to IFX in intestinal BS patients. Routine assessments of ESR, fT3, and fT3\/fT4 ratio are helpful to identify high-risk individuals of IFX refractory intestinal BS. Thalidomide is suggested to be a concomitant therapy with IFX for intestinal BS patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roab127","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T20:51:52Z","timestamp":1640119912000},"page":"207-216","source":"Crossref","is-referenced-by-count":10,"title":["Predictors of infliximab refractory intestinal Beh\u00e7et\u2019s syndrome: A retrospective cohort study from the Shanghai Beh\u00e7et\u2019s syndrome database"],"prefix":"10.1093","volume":"33","author":[{"given":"Hua-fang","family":"Bao","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Huadong Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-cheng","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Huadong Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Key Laboratory of Clinical Geriatric Medicine of Shanghai, Huadong Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Huadong Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Huadong Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-fei","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Huadong Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Huadong Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-long","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Huadong Hospital, Fudan University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,22]]},"reference":[{"key":"2023011210485774300_R1","first-page":"3","article-title":"One year in review 2020: Beh\u00e7et\u2019s syndrome","volume":"38 Suppl 127","author":"Hatemi","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2023011210485774300_R2","doi-asserted-by":"crossref","first-page":"iii101","DOI":"10.1093\/rheumatology\/kez626","article-title":"Beh\u00e7et: the syndrome","volume":"59","author":"Bettiol","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023011210485774300_R3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/1744666X.2016.1205486","article-title":"Behcet\u2019s disease: epidemiology, clinical manifestations, and diagnosis","volume":"13","author":"Davatchi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"2023011210485774300_R4","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02429-7","article-title":"Cluster analysis of phenotypes of patients with Beh\u00e7et\u2019s syndrome: a large cohort study from a referral center in China","volume":"23","author":"Zou","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2023011210485774300_R5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.5009\/gnl17462","article-title":"Anti-tumor necrosis factor therapy in intestinal Beh\u00e7et\u2019s disease","volume":"12","author":"Park","year":"2018","journal-title":"Gut Liver"},{"key":"2023011210485774300_R6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/BOR.0000000000000125","article-title":"An update on the diagnosis, treatment, and prognosis of intestinal Beh\u00e7et\u2019s disease","volume":"27","author":"Cheon","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"2023011210485774300_R7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","article-title":"The 2nd edition of consensus statements for the diagnosis and management of intestinal Beh\u00e7et\u2019s disease: indication of anti-TNF\u03b1 monoclonal antibodies","volume":"49","author":"Hisamatsu","year":"2014","journal-title":"J Gastroenterol"},{"key":"2023011210485774300_R8","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023011210485774300_R9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10620-016-4395-8","article-title":"Long-term outcomes and predictors of sustained response in patients with intestinal behcet\u2019s disease treated with infliximab","volume":"62","author":"Zou","year":"2017","journal-title":"Dig Dis Sci"},{"key":"2023011210485774300_R10","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e31828f19c9","article-title":"Efficacy of infliximab in intestinal Beh\u00e7et\u2019s disease: a Korean multicenter retrospective study","author":"Lee","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2023011210485774300_R11","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2169\/internalmedicine.52.0589","article-title":"Efficacy of infliximab in patients with intestinal Beh\u00e7et\u2019s disease refractory to conventional medication","volume":"52","author":"Kinoshita","year":"2013","journal-title":"Intern Med"},{"key":"2023011210485774300_R12","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1228-9","article-title":"Poor prognostic factors in patients with newly diagnosed intestinal Adamantiades-Beh\u00e7et\u2019s disease in the Shanghai Adamantiades-Beh\u00e7et\u2019s disease database: a prospective cohort study","volume":"14","author":"Zhang","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2023011210485774300_R13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD)","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023011210485774300_R14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ibd.21313","article-title":"Development, validation, and responsiveness of a novel disease activity index for intestinal Beh\u00e7et\u2019s disease","volume":"17","author":"Cheon","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2023011210485774300_R15","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s10620-014-3198-z","article-title":"Mucosal healing predicts the long-term prognosis of intestinal Beh\u00e7et\u2019s disease","volume":"59","author":"Yim","year":"2014","journal-title":"Dig Dis Sci"},{"key":"2023011210485774300_R16","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01772-x","article-title":"Clinical characteristics and risk factors of intestinal involvement in Beh\u00e7et\u2019s syndrome patients: a cross-sectional study from a single center","volume":"16","author":"Hou","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2023011210485774300_R17","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s00384-020-03679-8","article-title":"Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn\u2019s disease","volume":"35","author":"Xu","year":"2020","journal-title":"Int J Colorectal Dis"},{"key":"2023011210485774300_R18","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/j.1468-3083.2006.01553.x","article-title":"Baseline and stimulated thyroid functions in Beh\u00e7et\u2019s disease","volume":"20","author":"Akdeniz","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023011210485774300_R19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/956837","article-title":"Thyroid autoimmunity and Beh\u00e7et\u2019s disease: is there a significant association?","volume":"2013","author":"Cebeci","year":"2013","journal-title":"Sci World J"},{"key":"2023011210485774300_R20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1530\/JOE-10-0481","article-title":"Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease","volume":"209","author":"Maia","year":"2011","journal-title":"J Endocrinol"},{"key":"2023011210485774300_R21","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16167","article-title":"Serum triiodothyronine-to-thyroxine (T3\/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients","author":"Bertani","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2023011210485774300_R22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijsu.2018.02.001","article-title":"The non-thyroidal illness syndrome is associated with postoperative surgical site infections in enterocutaneous fistulae","volume":"51","author":"Ren","year":"2018","journal-title":"Int J Surg"},{"key":"2023011210485774300_R23","doi-asserted-by":"publisher","DOI":"10.5551\/jat.60624","article-title":"Low free triiodothyronine level as a predictor of cardiovascular events and all-cause mortality in patients undergoing hemodialysis: the DREAM cohort","author":"Yamazaki","year":"2021","journal-title":"J Atheroscler Thromb"},{"key":"2023011210485774300_R24","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jc.2011-1784","article-title":"Lower free thyroxin associates with a less favorable metabolic phenotype in healthy pregnant women","volume":"96","author":"Bassols","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2023011210485774300_R25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.numecd.2020.10.011","article-title":"Predictive value of free triiodothyronine (FT3) to free thyroxine (FT4) ratio in long-term outcomes of euthyroid patients with three-vessel coronary artery disease","volume":"31","author":"Yuan","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2023011210485774300_R26","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1210\/jc.2017-02149","article-title":"Degree of peripheral thyroxin deiodination, frailty, and long-term survival in hospitalized older patients","volume":"103","author":"Pasqualetti","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2023011210485774300_R27","first-page":"43","article-title":"Beh\u00e7et\u2019s syndrome and health-related quality of life: influence of symptoms, lifestyle and employment status","volume":"35 Suppl 108","author":"Senusi","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2023011210485774300_R28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ibd.20317","article-title":"Thalidomide for treatment of intestinal involvement of juvenile-onset Beh\u00e7et disease","volume":"14","author":"Yasui","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"2023011210485774300_R29","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of primary response to biologic treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2023011210485774300_R30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ebiom.2017.06.004","article-title":"Calprotectin and the magnitude of antibodies to infliximab in clinically-stable ulcerative colitis patients are more relevant than infliximab trough levels and pharmacokinetics for therapeutic escalation","volume":"21","author":"Magro","year":"2017","journal-title":"EBioMedicine"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roab127\/42602107\/roab127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/1\/207\/48626436\/roab127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/1\/207\/48626436\/roab127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T11:57:17Z","timestamp":1673524637000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/1\/207\/6474469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,22]]},"published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roab127","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2021,12,22]]}}}